MITOXCELAI Trademark
Trademark Overview
On Thursday, June 12, 2025, a trademark application was filed for MITOXCELAI with the United States Patent and Trademark Office. The USPTO has given the MITOXCELAI trademark a serial number of 99230657. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Thursday, June 4, 2026. This trademark is owned by SENOTHERAPEUTIX, Inc.. The MITOXCELAI trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Medical research services; Medical research in the field of mitochondrial health and mitochondrial disease; Medical research in the field of metabolic health and metabolic conditions; Medical research in the field of anti-aging; Medical research in the field of senescent cells; Medical research in the field of age-related disorders; Medical research in the field of neurodegenerative health and neurodegenerative disease; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Pharmaceutical research in the field of mitochondrial disease; Pharmaceutical research in the field of metabolic conditions; Pharmaceutical research in the field of neurodegenerative disease; Gene therapy research; Testing of pharmaceuticals for cell and gene therapies; Development of pharmaceuticals for cell and gene therapies
Medical services, namely, anti-aging services in the nature of providing preventative medical care and treatment of age-related disorders and age-related diseases; Medical services, namely, providing preventative care and treatment of cancer, age-related disorders, age-related diseases, skin conditions, radiation damage, obesity, mitochondrial disease, neurodegenerative disease, and metabolic conditions; Medical services in the field of mitochondrial health and mitochondrial disease; Medical services in the field of metabolic health and metabolic conditions; Medical services in the field of anti-aging; Medical services in the field of senescent cells; Medical services in the field of age-related disorders; Medical services in the field of neurodegenerative health and neurodegenerative disease; Medical advisory services; Medical testing services; Medical testing services relating to the diagnosis and treatment of disease
Synthesized peptides for the treatment of cancer, age-related disorders, age-related diseases, skin conditions, radiation damage, obesity, mitochondrial disease, neurodegenerative disease, and metabolic conditions; Pharmaceutical preparations for the treatment and prevention of cancer, age-related disorders, age-related diseases, skin conditions, radiation damage, obesity, mitochondrial disease, neurodegenerative disease, and metabolic conditions; Pharmaceutical preparations for gene therapy for the treatment of age-related disorders; Pharmaceutical preparations for gene therapy for the treatment of cancer; Medicated skin preparation for use in treating skin conditions, aging, mitochondrial conditions, and senescent cells
General Information
| Serial Number | 99230657 |
| Word Mark | MITOXCELAI |
| Filing Date | Thursday, June 12, 2025 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Thursday, June 4, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, June 23, 2026 |
Trademark Statements
| Goods and Services | Medical research services; Medical research in the field of mitochondrial health and mitochondrial disease; Medical research in the field of metabolic health and metabolic conditions; Medical research in the field of anti-aging; Medical research in the field of senescent cells; Medical research in the field of age-related disorders; Medical research in the field of neurodegenerative health and neurodegenerative disease; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Pharmaceutical research in the field of mitochondrial disease; Pharmaceutical research in the field of metabolic conditions; Pharmaceutical research in the field of neurodegenerative disease; Gene therapy research; Testing of pharmaceuticals for cell and gene therapies; Development of pharmaceuticals for cell and gene therapies |
| Goods and Services | Medical services, namely, anti-aging services in the nature of providing preventative medical care and treatment of age-related disorders and age-related diseases; Medical services, namely, providing preventative care and treatment of cancer, age-related disorders, age-related diseases, skin conditions, radiation damage, obesity, mitochondrial disease, neurodegenerative disease, and metabolic conditions; Medical services in the field of mitochondrial health and mitochondrial disease; Medical services in the field of metabolic health and metabolic conditions; Medical services in the field of anti-aging; Medical services in the field of senescent cells; Medical services in the field of age-related disorders; Medical services in the field of neurodegenerative health and neurodegenerative disease; Medical advisory services; Medical testing services; Medical testing services relating to the diagnosis and treatment of disease |
| Goods and Services | Synthesized peptides for the treatment of cancer, age-related disorders, age-related diseases, skin conditions, radiation damage, obesity, mitochondrial disease, neurodegenerative disease, and metabolic conditions; Pharmaceutical preparations for the treatment and prevention of cancer, age-related disorders, age-related diseases, skin conditions, radiation damage, obesity, mitochondrial disease, neurodegenerative disease, and metabolic conditions; Pharmaceutical preparations for gene therapy for the treatment of age-related disorders; Pharmaceutical preparations for gene therapy for the treatment of cancer; Medicated skin preparation for use in treating skin conditions, aging, mitochondrial conditions, and senescent cells |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 12, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 12, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 12, 2025 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | SENOTHERAPEUTIX, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Surfside, FL 33154
US |
Trademark Events
| Event Date | Event Description |
| Thursday, June 12, 2025 | NEW APPLICATION ENTERED |
| Thursday, June 12, 2025 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, October 22, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, October 31, 2025 | ASSIGNED TO EXAMINER |
| Tuesday, November 11, 2025 | NON-FINAL ACTION WRITTEN |
| Tuesday, November 11, 2025 | NON-FINAL ACTION E-MAILED |
| Tuesday, November 11, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, February 10, 2026 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Tuesday, February 10, 2026 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Thursday, May 7, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, May 7, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, May 7, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, May 29, 2026 | EXAMINERS AMENDMENT -WRITTEN |
| Friday, May 29, 2026 | EXAMINERS AMENDMENT E-MAILED |
| Friday, May 29, 2026 | EXAMINER'S AMENDMENT ENTERED |
| Friday, May 29, 2026 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Friday, May 29, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
